Procedure: motion analysis (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01882010 (ClinicalTrials.gov) | September 2013 | 13/6/2013 | Leukine (Sargramostim) for Parkinson's Disease | Leukine (Sargramostim) for Parkinson's Disease | Parkinson's Disease | Procedure: blood draw;Procedure: physical exam and UPDRS part III assessment;Procedure: MEG;Drug: sargramostim;Drug: placebo;Behavioral: physical exam and UPDRS part III assessment;Procedure: Motion Analysis | Howard Gendelman, MD | Sanofi;National Institute of Neurological Disorders and Stroke (NINDS);UNeMed;Nebraska Neuroscience Alliance | Completed | 35 Years | 85 Years | Both | 37 | Phase 1 | United States |